The Prognostic Implication of Preoperative Troponin Elevation at Hospital Admission in Hip Fracture Patients: A Systematic Review and Meta-Analysis
In brief
Hip fracture patients with high admission troponin had twice the mortality
In a meta-analysis of five studies involving 2,148 patients, elevated troponin at admission was associated with about twice the overall mortality, including higher mortality at one and three months. The association could help identify patients needing closer risk assessment, but the evidence was low to moderate certainty and does not show that troponin elevation causes deaths or that acting on the result improves outcomes.
- Journal
- The Journal of arthroplasty (Q1)
- Published
- 9 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Fernando Baldy de Sousa, Eric Pasqualotto, Tales Pasqualotto, Eduardo Campos Martins, Felipe de Almeida Osterne, Fernando Baldy Dos Reis
- PMID
- 43003362
- DOI
- 10.1016/j.arth.2026.11.034
Why clinicians should know about it
- Picked for Orthopedics and Sports Medicine (top studies of the week, 15 November 2026): Admission troponin predicts mortality after hip fracture
Abstract
BACKGROUND: The purpose of our study was to evaluate the prognostic significance of preoperative troponin elevation in patients who have hip fractures. METHODS: PubMed, Embase, and the Cochrane Library were systematically searched for randomized controlled trials (RCTs) or observational studies published up to December 2025 comparing patients who have elevated cardiac troponin levels at hospital admission with those presenting normal troponin levels in patients who have hip fractures. Risk ratios (RR) were used to evaluate binary outcomes and mean differences (MD) for continuous endpoints, with 95% confidence intervals (CI). RESULTS: A total of five studies comprising 2,148 patients who had hip fractures were included. The group with normal troponin at admission had significantly lower overall mortality compared to the group with elevated troponin (RR 2.11; 95% CI 1.63 to 2.74; P < 0.01). In a subgroup analysis, mortality at one month (RR 3.65; 95% CI 1.59 to 8.39; P < 0.01) and three months (RR 1.98; 95% CI 1.51 to 2.60; P < 0.01) was also significantly lower in patients with normal troponin at hospital admission. However, there were no significant differences between groups for arrhythmia, congestive heart failure, or lengths of hospital stay. CONCLUSIONS: Preoperative elevation of cardiac troponin at hospital admission was consistently associated with an increased risk of mortality, supported by low to moderate-certainty evidence. These findings support the potential role of admission troponin as an accessible prognostic biomarker for early risk stratification in this high-risk population.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.